Clinical Trials

Multiple Myeloma

NCT02719613 2026-04-15

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Phase 2 Completed

67 enrolled

Multiple Myeloma

NCT05623020 2026-04-15

MagnetisMM-6

1,116 enrolled

Multiple Myeloma

NCT07455851 2026-04-15

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Recruiting

150 enrolled

Multiple Myeloma

NCT06550895 2026-04-14

MonumenTAL-8

11 enrolled

Multiple Myeloma

NCT06615479 2026-04-14

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

440 enrolled

Multiple Myeloma, Recurrence

NCT07030517 2026-04-14

A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

Phase 4 Recruiting

75 enrolled

Multiple Myeloma

NCT07409246 2026-04-14

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

127 enrolled

Multiple Myeloma, Neoplasms

NCT07529782 2026-04-14

Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

15 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03301220 2026-04-13

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

390 enrolled 12 charts 3 FDA

Smoldering Multiple Myeloma

NCT03901963 2026-04-13

AURIGA

200 enrolled 12 charts

Multiple Myeloma

NCT04108195 2026-04-13

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

290 enrolled

Multiple Myeloma

NCT04133636 2026-04-13

CARTITUDE-2

210 enrolled

Multiple Myeloma

NCT04181827 2026-04-13

CARTITUDE-4

419 enrolled 10 charts

Multiple Myeloma

NCT04557150 2026-04-13

A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

Phase 1 Completed

225 enrolled

Multiple Myeloma

NCT04634552 2026-04-13

MonumenTAL-1

Other hematologic neoplasmPlasma cell

510 enrolled 2 FDA

Multiple Myeloma, Hematologic Neoplasms

NCT04722146 2026-04-13

MajesTEC-2

140 enrolled

Multiple Myeloma

NCT04923893 2026-04-13

CARTITUDE-5

743 enrolled

Multiple Myeloma

NCT05050097 2026-04-13

MonumenTAL-2

166 enrolled

Multiple Myeloma

NCT05083169 2026-04-13

MajesTEC-3

587 enrolled 2 FDA

Multiple Myeloma

NCT05201781 2026-04-13

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Phase 4 Recruiting

295 enrolled

Multiple Myeloma

NCT05438043 2026-04-13

A Study of Daratumumab

500 enrolled

Multiple Myeloma

NCT05455320 2026-04-13

MonumenTAL-3

864 enrolled

Multiple Myeloma, Recurrence

NCT05552222 2026-04-13

MajesTEC-7

1,590 enrolled

Multiple Myeloma

NCT05572515 2026-04-13

MajesTEC-9

614 enrolled

Multiple Myeloma, Recurrence

NCT05652335 2026-04-13

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

180 enrolled

Amyloidosis, Multiple Myeloma, Recurrence

NCT05675449 2026-04-13

MagnetisMM-20

59 enrolled

Multiple Myeloma, Recurrence

NCT05955508 2026-04-13

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

40 enrolled

Smoldering Multiple Myeloma, Multiple Myeloma

NCT06425991 2026-04-13

MajesTEC-10

108 enrolled

Multiple Myeloma, Recurrence

NCT06433947 2026-04-13

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

130 enrolled

Multiple Myeloma

NCT06500884 2026-04-13

Talisman

210 enrolled

Multiple Myeloma

NCT06577025 2026-04-13

aMMbition

43 enrolled

Multiple Myeloma

NCT06604715 2026-04-13

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

80 enrolled

Multiple Myeloma, Recurrence

NCT06669247 2026-04-13

COSTIMM

Phase 1/2 Recruiting

186 enrolled

Multiple Myeloma

NCT06768489 2026-04-13

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

140 enrolled

Multiple Myeloma

NCT06934044 2026-04-13

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

20 enrolled

Multiple Myeloma

NCT07149857 2026-04-13

CARTITUDE-10

60 enrolled

Multiple Myeloma

NCT07258511 2026-04-13

TRIlogy-4

400 enrolled

Multiple Myeloma

NCT07266441 2026-04-13

TRIlogy-3

157 enrolled

Phase 3 Not yet recruiting

Multiple Myeloma

NCT07518186 2026-04-13

TRIlogy-5

700 enrolled